Molecular biomarkers
T. Aoki (Toronto, Canada)
News on frontline advanced stage
P. Borchmann (Cologne, Germany)
News on frontline advanced stage
S.M. Smith (Chicago, USA)
Novel agents in relapse/refractory patients
R. Advani (Stanford, USA) N/A
SESSION II - PTCL/CTCL

New targeted agents in PTCL
S.P. Iyer (Houston, USA)
SESSION III - DLBCL (Excluded CAR-T)

Bispecific and beyond
C. Thieblemont (Paris, France)
SESSION IV - FOLLICULAR LYMPHOMA

DEBATE: Pro CAR-T
J.S. Abramson (Cambridge, USA)
DEBATE: Pro bispecifics
M. Hutchings (Copenhagen, Denmark)
SESSION V - LECTURES

BTK degraders update
A.V. Danilov (Duarte, USA)
SESSION VI - CAR-T Cells

SESSION VII - MANTELL CELL LYMPHOMA

The role of bispecifics
T.J. Phillips (Duarte, USA)